In order to investigate the association between polymorphisms of NER pathway and clinical outcomes of platinum-based chemotherapy, 1004 patients with advanced NSCLC who received only first-line platinum-based chemotherapy were enrolled in this study. This evidence concerns the gene NR1H2 and non-small cell lung carcinoma.